Axonics’ $150 Million Follow-On Public Offering


K&L Gates LLP advised Axonics Modulation Technologies on the deal.

Axonics Modulation Technologies (NASDAQ: AXNX) executed its public offering of 4 million shares of common stock, which raised $150 million in gross proceeds before underwriting discounts, commissions, and offering expenses.

Axonics is a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (SNM) devices for the treatment of bladder and bowel dysfunction, with net proceeds from this latest offering intended to support the technological enhancement and commercialization of Axonics’ r-SNM System in North America and Europe, SNM-related research and development activities, and general corporate purposes.

The K&L Gates team advising Axonics was led by Orange County office managing partner Michael Hedge (Picture), and also included partners Louis Cullman, Jason Dreibelbis, and Michael Hinckle, and associates Jacqulyn Lewis and Jacob Reichman.

Involved fees earner: Louis Cullman – K&L Gates; Jason Dreibelbis – K&L Gates; Michael Hedge – K&L Gates; Michael Hinckle – K&L Gates; Jacqulyn Lewis – K&L Gates;

Law Firms: K&L Gates;

Clients: Axonics Modulation Technologies, Inc;

Author: Ambrogio Visconti